Abstract:Human papillomavirus (HPV) vaccines based on HPV L1 virus-like particles (VLPs) are already licensed but not accessible worldwide. About 38.0 million people were living with HIV in 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against both viruses are an urgent need. In this study, the HIV-1 P18I10 CTL peptide from the V3 loop of HIV-1 gp120 glycoprotein was inserted into the HPV16 L1 protein to construct chimeric HPV:HIV (L1:P18I10) VLPs. Instead of the traditional baculovirus expression vector/insect cell (BEVS/IC) system, we established an alternative mammalian 293F cell-based expression system using cost-effective polyethylenimine-mediated transfection for L1:P18I10 protein production. Compared with conventional ultracentrifugation, we optimized a novel chromatographic purification method which could significantly increase L1:P18I10 VLP recovery (~56%). Chimeric L1:P18I10 VLPs purified from both methods were capable of self-assembling to integral particles and shared similar biophysical and morphological properties. After BALB/c mice immunization with 293F cell-derived and chromatography-purified L1:P18I10 VLPs, almost the same titer of anti-L1 IgG (p = 0.6409) was observed as Gardasil anti-HPV vaccine-immunized mice. Significant titers of anti-P18I10 binding antibodies (p < 0.01%) and P18I10-specific IFN-γ secreting splenocytes (p = 0.0002) were detected in L1:P18I10 VLP-immunized mice in comparison with licensed Gardasil-9 HPV vaccine. Furthermore, we demonstrated that insertion of HIV-1 P18I10 peptide into HPV16 L1 capsid protein did not affect the induction in anti-L1 antibodies. All in all, we expected that the mammalian cell expression system and chromatographic purification methods could be time-saving, cost-effective, scalable platforms to engineer bivalent VLP-based vaccines against HPV and HIV-1.

Comparison of PV Conformational Epitopes Expressed by L1 Proteins in Mammalian (COS) and Insect (SF9) Cells

In Vivo Characterization of Chimeric PCV DNA Clones Containing Heterogeneous Capsid Protein Nuclear Localization Signals (NLS).

Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice

Papillomavirus capsid binding and uptake by cells from different tissues and species

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

Candidate Peptide-Vaccine Induced Potent Protection Against Csfv and Identified A Principal Sequential Neutralizing Determinant on E2

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

The epitope of the VP1 protein of porcine parvovirus

Preparation of monoclonal antibody and identification of two novel B cell epitopes to VP1 protein of porcine sapelovirus

Expression and purification of HPV 18 L1 virus like particles and preparation of guinea pig antiserum against HPV 18 L1 VLP

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

A Pseudovirus Nanoparticle Displaying the Vaccinia Virus L1 Protein Elicited High Neutralizing Antibody Titers and Provided Complete Protection to Mice against Mortality Caused by a Vaccinia Virus Challenge

Screening and identification of B cell epitope within the major capsid protein L1 of HPV 52, using monoclonal antibodies

Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine Against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Identification of a Dominant Linear Epitope on the VP2 Capsid Protein of Porcine Parvovirus and Characterization of Two Monoclonal Antibodies with Neutralizing Abilities.

Prokaryotic Expression and Purification of Minor Capsid Protein L2 Derived from Human Papillomavirus 58 and Preparation of Monoclonal Antibody

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid Protein L2